Xenetic Biosciences (XBIO) Competitors

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Evaxion A/S had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Evaxion A/S and 2 mentions for Xenetic Biosciences. Evaxion A/S's average media sentiment score of 0.62 beat Xenetic Biosciences' score of 0.43 indicating that Evaxion A/S is being referred to more favorably in the media.

Evaxion A/S has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Evaxion A/S's return on equity.

Xenetic Biosciences has lower revenue, but higher earnings than Evaxion A/S. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 252.56%. Given Evaxion A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Evaxion A/S is more favorable than Xenetic Biosciences.

In the previous week, Barinthus Biotherapeutics and Barinthus Biotherapeutics both had 2 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 0.44 beat Xenetic Biosciences' score of 0.43 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Barinthus Biotherapeutics has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Xenetic Biosciences has lower revenue, but higher earnings than Barinthus Biotherapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Barinthus Biotherapeutics' return on equity.

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Barinthus Biotherapeutics currently has a consensus price target of $4.00, indicating a potential upside of 501.50%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Barinthus Biotherapeutics is more favorable than Xenetic Biosciences.

Xenetic Biosciences has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Greenland Mines Ltd. Common Stock has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Greenland Mines Ltd. Common Stock's return on equity.

Xenetic Biosciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.05, meaning that its stock price is 605% more volatile than the broader market.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Greenland Mines Ltd. Common Stock had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Greenland Mines Ltd. Common Stock and 2 mentions for Xenetic Biosciences. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.52 beat Xenetic Biosciences' score of 0.43 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media.

Marker Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, Marker Therapeutics and Marker Therapeutics both had 2 articles in the media. Marker Therapeutics' average media sentiment score of 1.44 beat Xenetic Biosciences' score of 0.43 indicating that Marker Therapeutics is being referred to more favorably in the media.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 646.27%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Marker Therapeutics is more favorable than Xenetic Biosciences.

Xenetic Biosciences has a net margin of -70.03% compared to Marker Therapeutics' net margin of -343.03%. Xenetic Biosciences' return on equity of -39.28% beat Marker Therapeutics' return on equity.

Xenetic Biosciences has lower revenue, but higher earnings than Marker Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.